NPN October 2026 Virtual Connections: Pipeline to Patient

October 15, 2026

Participants will explore the rapidly evolving field of cell and gene therapy, including recent FDA-approved therapies, emerging treatment innovations, and future developments in the pipeline. The activity will examine key clinical considerations such as patient selection, safety monitoring, and adverse event management, while also addressing the operational, regulatory, reimbursement, and implementation challenges health systems may encounter. Learners will gain practical insights into how multidisciplinary teams can prepare for, evaluate, and optimize the delivery of cell and gene therapies to improve patient outcomes.

Target Audience

Pharmacists
Pharmacy Technicians
Other Healthcare Professionals

Learning Objectives

At the conclusion of this activity, pharmacists should be able to:

Describe recent FDA-approved and emerging cell and gene therapies.
Evaluate key safety considerations, monitoring parameters, and adverse effect management strategies associated with cell and gene therapies.
Discuss operational, regulatory, and logistical considerations for implementing cell and gene therapy programs within health systems.
Apply current evidence and clinical guidelines to optimize patient selection and therapeutic outcomes in cell and gene therapy.

At the conclusion of this activity, pharmacy technicians should be able to:

Describe recent FDA-approved and emerging cell and gene therapies.
Discuss operational, regulatory, and logistical considerations for implementing cell and gene therapy programs within health systems.

Course summary

Available credit:

1.00 ACPE Pharmacist
1.00 ACPE Pharmacy Technician
0.10 IACET

Course opens:

10/15/2026

Course expires:

12/14/2026

Event starts:

10/15/2026 - 1:20pm CDT

Event ends:

10/15/2026 - 2:20pm CDT

Add to calendar:

FACULTY & PLANNERS

Faculty

Emily Diehl, PharmD, BCPPS
Senior Pharmacy Executive
Vizient

Planners

Madalene Klocke, MFA
Project Manager
Vizient

Emily Diehl, PharmD, BCPPS
Senior Pharmacy Executive
Vizient

Brook DesRivieres, PharmD, MS, LSSGB, FACHE
Pharmacy Executive IV
Vizient

Marilu Kelly, MSN, RN, NPD-BC, CHCP
Director, Continuing Education
Vizient

Kim Bentley, CHCP
CE Programs Manager
Vizient

DISCLOSURE

As an accredited provider of continuing education, Vizient, Inc. is dedicated to ensuring this activity presents learners with only accurate, balanced, scientifically justified recommendations, and is free from promotion, marketing, and commercial bias. In accordance with The Standards for Integrity and Independence in Accredited Continuing Education, all planners, faculty, and others in control of the educational content have disclosed the absence or existence of all financial relationships (of any dollar amount) with ineligible companies within the past 24 months.

Ineligible companies – those companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

It is Vizient’s policy that owners and employees of ineligible companies, and any individuals who refuse to disclose the absence or existence of financial relationships with any ineligible companies are disqualified from participating as planners or faculty.

Statement of Content Validity

Vizient, Inc. educational activities are intended to assist healthcare teams advance their professional responsibilities in accordance with the definition of continuing education. It is the policy of Vizient, Inc. to review and ensure that all content and recommendations for patient care within accredited CE is evidenced-based, based on current science and clinical reasoning while ensuring the content is fair and balanced. All recommendations must conform to the generally accepted standards of experimental design, data collection, analysis, and interpretation. Vizient, Inc. does not permit accredited continuing education if it advocates for unscientific approaches to diagnosis or therapy, or if the education promotes recommendations, treatment, or manners of practicing healthcare that are determined to have risks or dangers that outweigh the benefits or are known to be ineffective in the treatment of patients.

FDA Off-Label Use

Faculty presenters are also expected to disclose any discussion of (1) off-label or investigational uses of FDA approved commercial products or devices or (2) products or devices not yet approved in the United States.

Disclaimer

The education provided through this activity is for continuing education purposes only. The views and opinions expressed in this activity are those of the faculty/presenters and do not necessarily reflect the views of Vizient, Inc.

Disclosure Statements

Absence of Relevant Financial Relationships

None of the planners, faculty, or others in a position to control content for this educational activity have relevant financial relationship(s) to disclose with ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

Course Director(s)